The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma

Endocrine Practice

Volumn 19, Issue 6, 2013, Pages

  Neto, Leonardo ^a,b   Chimelli, Leila ^c   Da M Pereira, Paulo ^d   Gasparetto, Emerson ^a,e   Bines, José ^f   Wildemberg, Luiz ^a   Gadelha, Mônica ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Federal Hospital of Lagoa   (United States)

^c The National Institute of Cancer   (United States)

^d Neurosurgery Section   (United States)

^e Centro de Diagnóstico Por Imagem CDPI   (United States)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C; TEMOZOLOMIDE; ZOLEDRONIC ACID;

ACROMEGALY; ADENOMA; ADULT; AMENORRHEA; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CANCER SIZE; CARCINOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; NONFUNCTIONING PITUITARY ADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; SELLA TURCICA; SOMATOTROPH PITUITARY CARCINOMA; TRANSSPHENOIDAL SURGERY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DACARBAZINE; DIPHOSPHONATES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; PITUITARY NEOPLASMS;

EID: 84888882564     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12400.CR     Document Type: Article

References (26)

1. Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course-case report and review of the literature. J Clin Endocrinol Metab. 2011;96:2665-2669.
2. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90:3089-3099.
3. Lopes MB, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine. 2005;28:115-121.
4. Asai A, Matsutani M, Funada N, Takakura K. Malignant growth hormone-secreting pituitary adenoma with hematogenous dural metastasis: case report. Neurosurgery. 1988; 22:1091-1094.
5. Dayan C, Guilding T, Hearing S, et al. Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastases. Clin Endocrinol (Oxf). 1996;44:597-602.
6. Greenman Y, Woolf P, Coniglio J, et al. Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. J Clin Endocrinol Metab. 1996;81:1628-1633.
7. Hashimoto N, Handa H, Nishi S. Intracranial and intraspinal dissemination from a growth hormone-secreting pituitary tumor. Case report. J Neurosurg. 1986;64:140-144.
8. Jamjoom A, Moss T, Coakham H, Jamjoom ZA, Anthony P. Cervical lymph nodes metastases from a pituitary carcinoma. Br J Neurosurg. 1994;8:87-92.
9. le Roux CW, Mulla A, Meeran K. Pituitary carcinoma as a cause of acromegaly. N Engl J Med. 2001;345:1645-1646.
10. Mountcastle RB, Roof BS, Mayfield RK, et al. Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci. 1989;298:109-118.
11. Scheithauer BW, Fereidooni F, Horvath E, et al. Pituitary carcinoma: an ultrastructural study of eleven cases. Ultrastruct Pathol. 2001;25:227-242.
12. Stewart PM, Carey MP, Graham CT, Wright AD, London DR. Growth hormone secreting pituitary carcinoma: a case report and literature review. Clin Endocrinol (Oxf). 1992; 37:189-194.
13. Yamashita S, Izumi M, Nagataki S. Acromegaly and pituitary carcinoma. Ann Intern Med. 1992;117:1057-1058.
14. Zahedi A, Booth GL, Smyth HS, et al. Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clin Endocrinol (Oxf). 2001;55:549-556.
15. Annamalai AK, Dean AF, Kandasamy N, et al. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary. 2012;15:276-287.
16. Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76:769-775.
17. Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology. 2011;94:39-48.
18. Lloyd RV, Kovacs K, Young WF, Jr., et al. Pituitary tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of tumours Pathology and Genetics of Tumors of Endocrine Organs. Lyon, France: IARC Press, 2004: 10-3.
19. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99-106.
20. Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest. 2010;28:944-957.
21. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7:518-20.
22. Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95:E280-290.
23. Hagen C, Schroeder HD, Hansen S, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161:631-637.
24. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
25. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary. 2010;13:367-379.
26. McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011;41: 1133-1148.